Literature DB >> 4005839

Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines.

A Fojo, S Akiyama, M M Gottesman, I Pastan.   

Abstract

Human KB cells with increasing resistance to colchicine and other chemotherapeutic agents have been isolated in four sequential steps. This report describes the characterization of drug uptake in the parent and four mutant cell lines. Drug uptake in these cell lines occurred via a nonsaturable process. In general, drug accumulation decreased with increasing drug resistance; this relationship was seen best with colchicine, vincristine, vinblastine, and daunomycin and, to a lesser extent, with actinomycin D. The accumulation of dexamethasone, an agent to which all lines were equally sensitive, was similar for the parent and the four mutants. Drug efflux occurred rapidly, and differences among the various cell lines could be detected within the first minute. In the more resistant lines, a greater percentage of the drug was released more rapidly, although the absolute amount of drug released was less. Verapamil partially reversed the multiple drug-resistance phenotype by increasing the initial rate of uptake and accumulation of drugs in the resistant cell lines without an apparent effect on drug efflux. The results suggest that, in this human epithelial cell, the development of resistance to multiple drugs is complex, with changes in drug uptake, accumulation, and efflux.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005839

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  93 in total

1.  Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.

Authors:  N Baldini; K Scotlandi; M Serra; K Kusuzaki; T Shikita; M C Manara; D Maurici; M Campanacci
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani.

Authors:  Bidyut Purkait; Ashish Kumar; Nilay Nandi; Abul Hasan Sardar; Sushmita Das; Sudeep Kumar; Krishna Pandey; Vidyananda Ravidas; Manish Kumar; Tripti De; Dharmendra Singh; Pradeep Das
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

3.  The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene.

Authors:  Michael M Gottesman; Ira H Pastan
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

Review 4.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 5.  Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.

Authors:  Vahab Ali; Tomoyoshi Nozaki
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

6.  Intracellular distribution of anthracyclines in drug resistant cells.

Authors:  G Arancia; A Calcabrini; S Meschini; A Molinari
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

7.  Expression of a multidrug-resistance gene in human tumors and tissues.

Authors:  A T Fojo; K Ueda; D J Slamon; D G Poplack; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

Review 8.  Genetic basis of multidrug resistance of tumor cells.

Authors:  S E Kane; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1990-08       Impact factor: 2.945

9.  Functional analysis of chimeric genes obtained by exchanging homologous domains of the mouse mdr1 and mdr2 genes.

Authors:  E Buschman; P Gros
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

10.  Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.

Authors:  S Scala; A Budillon; Z Zhan; Y S Cho-Chung; J Jefferson; M Tsokos; S E Bates
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.